Exicure Inc. (XCUR), an early-stage biotechnology company, announced on Thursday a co-development agreement with Korean biotechnology company Adbiotech Co. Ltd., for combination therapies with Burixafor in treating haematological indications.
Burixafor (GPC-100) is an investigational drug developed to treat varied indications such as sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors. It previously completed a successful Phase 2 clinical trial for multiple myeloma, and is currently being explored for other haematological indications.
As part of the agreement, Adbiotech will conduct in vitro studies for preclinical validation and translational research, while Exicure is expected to lead clinical and regulatory strategy for the drug's development.
The companies are directing efforts toward studies enabling an investigational new drug (IND) submission for burixafor.
XCUR is currently trading at $3.64, up 0.05%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.